COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Usefulness of Selegiline as an Aid to Quit Smoking - 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00129311
Recruitment Status : Completed
First Posted : August 11, 2005
Results First Posted : July 16, 2014
Last Update Posted : March 31, 2015
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Yale University

Brief Summary:
Despite the widespread use of nicotine replacement therapies for the treatment of nicotine dependence, many smokers are still unable to quit smoking. The purpose of this study is to determine the safety and effectiveness of selegiline as an aid to help smokers quit smoking.

Condition or disease Intervention/treatment Phase
Tobacco Use Cessation Drug: Selegiline Drug: Placebo Phase 2

Detailed Description:

Despite the availability of nicotine replacement therapies and sustained-relapse bupropion for the treatment of nicotine dependence, there is still a significant proportion of cigarette smokers who are unable to quit smoking. Therefore, new and effective pharmacotherapies for smoking cessation are needed. The primary aim of this study is to determine the safety and efficacy of selegiline as an aid to smoking cessation.

In this study, 200 nicotine-dependent cigarette smokers will participate in an 8-week, double-blind, placebo-controlled trial and then will be followed over 4 years. Participants will be randomly assigned to receive either selegiline or placebo. Selegiline doses of 5 mg will be taken once a day during the first week. This will be increased to 5 mg twice daily for the remaining 7 weeks. The target smoking "quit date" will be Day 15. All smokers will receive brief weekly manualized smoking cessation counseling from the Mayo Clinic's "Smoke Free and Livin' It" program. The primary smoking cessation outcome measure will be 7-day point prevalence smoking abstinence at the 6-month follow-up. Secondary cessation outcome measures will include continuous smoking abstinence during the last four weeks of the trial (Days 29-56) and 7-day point prevalence abstinence at the end of the 8-week trial (Days 49-56).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 101 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Usefulness of Selegiline for Smoking Cessation
Study Start Date : July 2004
Actual Primary Completion Date : December 2012
Actual Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Smoking
Drug Information available for: Selegiline

Arm Intervention/treatment
Experimental: 1
Drug: Selegiline
5 mg capsules taken by mouth. Participants take 5 mg once a day for the first week of the study, then increase the dose to 5 mg twice a day for 6 weeks, then take 5 mg once a day during the last week of the study. Participants receiving the placebo pill take 1 pill per day for the first week of the study and 1 pill twice a day for the other weeks.
Other Name: L-deprenyl; Eldepryl®

Placebo Comparator: 2
Drug: Placebo

Primary Outcome Measures :
  1. 7 Day Point Prevalence of Cigarette Abstinence [ Time Frame: 6-month follow up ]
  2. 7 Day Point Prevalence of Cigarette Abstinence [ Time Frame: Week 8 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Meets DSM-IV criteria for nicotine dependence with a Fagerstrom Test of Nicotine Dependence (FTND) score greater than 5
  • Smokes at least 15 cigarettes daily (averaged over 1 week, within the month prior to enrollment)
  • Motivated to quit smoking within 30 days at time of initial evaluation
  • At least one unsuccessful attempt to quit smoking in the past year
  • An expired breath CO level greater than 10 ppm and baseline plasma cotinine level greater than 150 ng/ml at initial evaluation
  • Body weight of at least 100 lb
  • Avoidance of nicotine replacement product use one month prior to enrollment
  • Speaks English

Exclusion Criteria:

  • Currently taking over-the-counter or prescription sympathomimetic agents (e.g., pseudoephedrine, methylphenidate), antidepressant agents (e.g., tricyclic antidepressants, serotonin reuptake inhibitors, bupropion, other monoamine oxidase inhibitors), or meperidine (Demerol)
  • Serious medical disorders such as unstable angina or liver failure
  • Abnormalities in baseline bloodwork (e.g., threefold elevation of liver function tests, electrolyte abnormalities)
  • Physiologically dependent on and/or abusing alcohol or other drugs of abuse (e.g., cocaine, opiates, benzodiazepines, etc.) during the 6 months prior to enrollment (based on a clinical evaluation, which includes a self-report, and is confirmed by a positive urine toxicology screen)
  • Meets DSM-IV criteria for a current diagnosis of major depressive disorder, panic disorder, or post-traumatic stress disorder
  • Current or past history of bipolar disorder or schizophrenia
  • Past history of major depression associated with historical evidence of suicidal or homicidal behavior, or psychotic symptoms
  • Currently residing with another study participant
  • Presence of suicidal or homicidal ideation
  • Significant impairment of social or occupational functioning, either at time of initial evaluation or during the trial
  • Known hypersensitivity to selegiline hydrochloride

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00129311

Layout table for location information
United States, Connecticut
New Haven, Connecticut, United States, 06511
Sponsors and Collaborators
Yale University
National Institute on Drug Abuse (NIDA)
Layout table for investigator information
Principal Investigator: Tony P George, M.D. Yale University
Principal Investigator: Marc N Potenza, M.D., Ph.D. Yale University

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Yale University Identifier: NCT00129311    
Other Study ID Numbers: NIDA-15757-1
R01DA015757 ( U.S. NIH Grant/Contract )
First Posted: August 11, 2005    Key Record Dates
Results First Posted: July 16, 2014
Last Update Posted: March 31, 2015
Last Verified: July 2014
Keywords provided by Yale University: